Evidence map›Paper›PMID 39848983›Full record

ArticleScientific reports2025

YAT2150 is irresistible in Plasmodium falciparum and active against Plasmodium vivax and Leishmania clinical isolates.

Inés Bouzón-Arnáiz, Mukul Rawat, Rachael Coyle, Lionel Brice Feufack-Donfack, Malen Ea, Agnes Orban, Jean Popovici, Lucía Román-Álamo, Antonino Nicolò Fallica, Bárbara Domínguez-Asenjo and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Inés Bouzón-ArnáizBarcelona Institute for Global Health (ISGlobal, Hospital Clínic-University of Barcelona), Rosselló 149-153, Barcelona, 08036, Spain.
Mukul RawatWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, CB10 1SA, UK.
Rachael CoyleWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, CB10 1SA, UK.
Lionel Brice Feufack-DonfackMalaria Research Unit, Institut Pasteur du Cambodge, 5 Boulevard Monivong, 120210, Phnom Penh, Cambodia.
Malen EaMalaria Research Unit, Institut Pasteur du Cambodge, 5 Boulevard Monivong, 120210, Phnom Penh, Cambodia.
Agnes OrbanMalaria Research Unit, Institut Pasteur du Cambodge, 5 Boulevard Monivong, 120210, Phnom Penh, Cambodia.
Jean PopoviciMalaria Research Unit, Institut Pasteur du Cambodge, 5 Boulevard Monivong, 120210, Phnom Penh, Cambodia.
Lucía Román-ÁlamoBarcelona Institute for Global Health (ISGlobal, Hospital Clínic-University of Barcelona), Rosselló 149-153, Barcelona, 08036, Spain.
Antonino Nicolò FallicaBarcelona Institute for Global Health (ISGlobal, Hospital Clínic-University of Barcelona), Rosselló 149-153, Barcelona, 08036, Spain.
Bárbara Domínguez-AsenjoWHO Collaborating Centre for Leishmaniasis, National Centre for Microbiology Instituto de Salud Carlos III, Majadahonda, 28220, Spain.
Javier MorenoWHO Collaborating Centre for Leishmaniasis, National Centre for Microbiology Instituto de Salud Carlos III, Majadahonda, 28220, Spain.
Elsa M ArceLaboratory of Medicinal Chemistry, Faculty of Pharmacy and Food Sciences, University of Barcelona, Av. Joan XXIII, 27-31, Barcelona, 08028, Spain.
Ana Mallo-AbreuLaboratory of Medicinal Chemistry, Faculty of Pharmacy and Food Sciences, University of Barcelona, Av. Joan XXIII, 27-31, Barcelona, 08028, Spain.
Diego Muñoz-TorreroLaboratory of Medicinal Chemistry, Faculty of Pharmacy and Food Sciences, University of Barcelona, Av. Joan XXIII, 27-31, Barcelona, 08028, Spain.
Marcus C S LeeWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, CB10 1SA, UK.
Xavier Fernàndez-BusquetsBarcelona Institute for Global Health (ISGlobal, Hospital Clínic-University of Barcelona), Rosselló 149-153, Barcelona, 08036, Spain. xfernandez@ibecbarcelona.eu.

Funding

Extent, dynamics and mechanisms of Plasmodium vivax immune evasion caused by PvDBP gene amplificationR01AI173171 · NIAID · INSTITUT PASTEUR DU CAMBODGE · PI Eugenia Lo, Jean POPOVICI · 2023 to 2026
$2.4M
Comprehensive characterization of the genetic factors and the host immune response associated to protection from clinical Plasmodium vivax malariaR01AI175134 · NIAID · INSTITUT PASTEUR DU CAMBODGE · PI TINEKE CANTAERT, Jean POPOVICI · 2023 to 2026
$2.3M
Bill and Melinda Gates Foundation OPP1054480Ministerio de Ciencia e Innovación PID2020-118127RB-I00Ministerio de Ciencia e Innovación PID2021-128325OB-I00Ministerio de Ciencia e Innovación,Spain FJC2021-047571-IMinisterio de Ciencia e Innovación,Spain PDC2022-133085-I00National Institutes of Health,United States R01AI173171NIAID NIH HHS R01 AI173171NIAID NIH HHS R01 AI175134NIH HHS R01AI175134
6 · The paper itself

Abstract

We recently characterized the potent antiplasmodial activity of the aggregated protein dye YAT2150, whose presumed mode of action is the inhibition of protein aggregation in the malaria parasite. Using single-dose and ramping methods, assays were done to select Plasmodium falciparum parasites resistant to YAT2150 concentrations ranging from 3× to 0.25× the in vitro IC

Indexed as

AntimalarialsLeishmania infantumPlasmodium falciparumPlasmodium vivaxDrug ResistanceHumansInhibitory Concentration 50Parasitic Sensitivity TestsAntimalarials

Identifiers

PMID39848983
PMCPMC11758391

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.